Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

BACKGROUND: Dinaciclib is a potent inhibitor of cell cycle and transcriptional cyclin-dependent kinases. This Phase 1 study evaluated the safety, tolerability and pharmacokinetics of various dosing schedules of dinaciclib in advanced solid tumour patients and assessed pharmacodynamic and preliminary...

Descripción completa

Detalles Bibliográficos
Autores principales: Mita, Monica M, Mita, Alain C, Moseley, Jennifer L, Poon, Jennifer, Small, Karen A, Jou, Ying-Ming, Kirschmeier, Paul, Zhang, Da, Zhu, Yali, Statkevich, Paul, Sankhala, Kamelesh K, Sarantopoulos, John, Cleary, James M, Chirieac, Lucian R, Rodig, Scott J, Bannerji, Rajat, Shapiro, Geoffrey I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672931/
https://www.ncbi.nlm.nih.gov/pubmed/28859059
http://dx.doi.org/10.1038/bjc.2017.288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672931/
https://www.ncbi.nlm.nih.gov/pubmed/28859059
http://dx.doi.org/10.1038/bjc.2017.288

Ejemplares similares